What funding and validation does RMS have?

RMS’s research program is supported by grant funding from the National Institutes of Health (NIH), a significant marker of scientific validation for a company at the preclinical stage. NIH funding is awarded on the basis of rigorous peer review and represents external recognition of the scientific merit and potential impact of RMS’s work.

In addition to grant funding, RMS has built a substantial intellectual property portfolio, including multiple issued patents related to stem cell differentiation and islet-like cluster development. These patents protect RMS’s proprietary differentiation protocols and cell technologies, and represent a core component of the company’s long-term commercial value.

RMS also holds a non-exclusive license from Academia Sinica to practice iPSC methods for both research tools and therapy applications. The company’s scientific credibility is further reinforced by its origins in the University of Wisconsin–Madison research program and by the track record of its founding scientist, Dr. Jon Odorico, whose work has been published in leading peer-reviewed journals.

View RMS’s patents, licenses and grants.